Venus Remedies vs Sakar Healthcare vs Dishman Carbogen: Which Stock Should You Track

Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis: Company Overview

Venus Remedies is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,240 crore, a return on equity of 15.49% and a book value of Rs 496.56 per share. Its quarterly revenue moved from Rs 140.59 crore in June 2025 to Rs 181.48 crore in June 2026, a change of +29.1%.

Sakar Healthcare is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,230 crore, a return on equity of 9.40% and a book value of Rs 145.82 per share. Its quarterly revenue moved from Rs 53.13 crore in June 2025 to Rs 74.51 crore in June 2026, a change of +40.2%.

Dishman Carbogen Amcis is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,301 crore, a return on equity of 1.46% and a book value of Rs 425.87 per share. Its quarterly revenue moved from Rs 732.80 crore in June 2025 to Rs 695.80 crore in June 2026, a change of -5.0%.

Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis: Valuation and Profitability Snapshot

Metric	Venus Remedies	Sakar Healthcare	Dishman Carbogen Amcis
Market Cap (approx.)	Rs 2,240 crore	Rs 2,230 crore	Rs 2,301 crore
PE Ratio (TTM)	19.28	61.80	142.48
PB Ratio	3.38	6.87	0.34
Return on Equity (ROE)	15.49%	9.40%	1.46%
EPS (TTM, Rs)	86.92	16.22	1.03
Dividend Yield	0.60%	0.00%	0.00%
Debt to Equity	0.02	0.17	0.46
Book Value per Share (Rs)	496.56	145.82	425.87

Check the Univest Screener for Live Data

On valuation, Venus Remedies trades at a PE of 19.28 and a PB of 3.38, Sakar Healthcare at a PE of 61.80 and a PB of 6.87, while Dishman Carbogen Amcis trades at a PE of 142.48 and a PB of 0.34. On return on equity, the three post 15.49%, 9.40% and 1.46% respectively, and on dividend yield they stand at 0.60%, 0.00% and 0.00%. Dishman Carbogen Amcis has the highest market capitalisation of the three at Rs 2,301 crore, while Sakar Healthcare has the lowest at Rs 2,230 crore. Dishman Carbogen Amcis has the highest PE ratio of the three at 142.48, while Venus Remedies has the lowest at 19.28. Venus Remedies has the highest return on equity of the three at 15.49%, while Dishman Carbogen Amcis has the lowest at 1.46%. Dishman Carbogen Amcis has the highest debt to equity ratio of the three at 0.46, while Venus Remedies has the lowest at 0.02. Debt to equity is 0.02, 0.17 and 0.46 for the three respectively.

Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Venus Remedies	Rs 181.48 crore	Rs 22.97 crore	+29.1%	-31.3%	+139.3%
Sakar Healthcare	Rs 74.51 crore	Rs 10.28 crore	+40.2%	+4.5%	+120.1%
Dishman Carbogen Amcis	Rs 695.80 crore	-Rs 57.88 crore	-5.0%	-19.8%	-347.2%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Venus Remedies	Sakar Healthcare	Dishman Carbogen Amcis
June 2025	Rs 140.59 crore	Rs 53.13 crore	Rs 732.80 crore
September 2025	Rs 194.46 crore	Rs 58.77 crore	Rs 660.76 crore
December 2025	Rs 182.78 crore	Rs 70.85 crore	Rs 726.46 crore
March 2026	Rs 264.35 crore	Rs 71.27 crore	Rs 867.82 crore
June 2026	Rs 181.48 crore	Rs 74.51 crore	Rs 695.80 crore

Quarterly net profit (Rs crore)

Quarter	Venus Remedies	Sakar Healthcare	Dishman Carbogen Amcis
June 2025	Rs 9.60 crore	Rs 4.67 crore	Rs 23.41 crore
September 2025	Rs 20.13 crore	Rs 4.54 crore	Rs 65.27 crore
December 2025	Rs 25.58 crore	Rs 10.25 crore	-Rs 12.97 crore
March 2026	Rs 47.50 crore	Rs 11.02 crore	Rs 21.74 crore
June 2026	Rs 22.97 crore	Rs 10.28 crore	-Rs 57.88 crore

Venus Remedies reported revenue of Rs 140.59 crore in June 2025 and Rs 181.48 crore in June 2026, a change of +29.1% across the period. Its highest quarterly revenue in this window was Rs 264.35 crore in March 2026. Net profit stood at Rs 22.97 crore in June 2026, which is a net profit margin of 12.66%.

Sakar Healthcare reported revenue of Rs 53.13 crore in June 2025 and Rs 74.51 crore in June 2026, a change of +40.2% across the period. Its highest quarterly revenue in this window was Rs 74.51 crore in June 2026. Net profit stood at Rs 10.28 crore in June 2026, which is a net profit margin of 13.80%.

Dishman Carbogen Amcis reported revenue of Rs 732.80 crore in June 2025 and Rs 695.80 crore in June 2026, a change of -5.0% across the period. Its highest quarterly revenue in this window was Rs 867.82 crore in March 2026. Net profit stood at -Rs 57.88 crore in June 2026, which is a net profit margin of -8.32% (a net loss for the quarter). Dishman Carbogen Amcis reported a net loss in December 2025 and June 2026.

Download the Univest iOS App or Univest Android App to track Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Venus Remedies vs Sakar Healthcare vs Dishman Carbogen Amcis

What is the market cap difference between Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis?

Ans. As of October 2026, Venus Remedies has a market cap of approximately Rs 2,240 crore, Sakar Healthcare is at approximately Rs 2,230 crore, and Dishman Carbogen Amcis is at approximately Rs 2,301 crore.

What are the PE and PB ratios of Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis?

Ans. As of October 2026, the PE ratios stand at 19.28, 61.80 and 142.48 respectively, and the price to book ratios stand at 3.38, 6.87 and 0.34 respectively.

Which of the three has the highest ROE?

Ans. Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis post ROE of 15.49%, 9.40% and 1.46% respectively as of October 2026. Venus Remedies has the highest return on equity of the three at 15.49%, while Dishman Carbogen Amcis has the lowest at 1.46%.

Which of these three stocks pays the highest dividend yield?

Ans. Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis carry dividend yields of 0.60%, 0.00% and 0.00% respectively.

What is the debt to equity ratio for Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis?

Ans. Venus Remedies carries a debt to equity of 0.02, Sakar Healthcare of 0.17, and Dishman Carbogen Amcis of 0.46.

What were the latest quarterly revenue and net profit of Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis?

Ans. For Q1 FY27 (quarter ended June 2026), Venus Remedies reported revenue of Rs 181.48 crore and net profit of Rs 22.97 crore, Sakar Healthcare reported revenue of Rs 74.51 crore and net profit of Rs 10.28 crore, and Dishman Carbogen Amcis reported revenue of Rs 695.80 crore and net profit of -Rs 57.88 crore.

Does this comparison recommend one of Venus Remedies, Sakar Healthcare and Dishman Carbogen Amcis?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.